Table 2.

Summary of the various nanosystems used for treating genetic disorders.

Genetic Disease	Nanosystem	Effects	Ref.
Alzheimer’s Disease	Solid lipid nanoparticles (SLNs) PLGA NPs conjugated with Tet-1 peptide	inhibited Aβ aggregation improved cellular uptake	[189,190,205]
Parkinson’s Disease	Retinoic acid NPs	Increased bioavailability of loaded compounds, prevented apoptosis, oxidative stress, and toxicity	[213,214]
Amyotrophic Lateral Sclerosis	Calcium phosphate lipid-coated NPs	able to pass through the BBB, neutralized RNS and ROS reactions	[218,219]
Huntington’s Disease	Curcumin SLN	Reduced the activity of intermediate complex II	[224,227]
	Trehalose-loaded zwitterion NPs	Inhibited amyloid and polyglutamine aggregation
Cystic Fibrosis	Lipid NPs	Increased the amount of membrane-localized CFTR	[230,231]
	PLGA NPs coated with PEG	Effectively delivered anti-inflammatory compounds